Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
IMUX Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IMUX Stock 12 Month Forecast
Average Price Target
$4.25
▲(645.61% Upside)
| Highest Price Target$8.00 | Average Price Target$4.25 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
Buy
―
Reiterated
12/15/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Immunic (NASDAQ: IMUX)We continue to view vidofludimus calcium as a potent next-generation DHODH inhibitor and additional Nurr1 activation may provide additionalneuroprotection over teriflunomide without the need for liver monitoring. However, with $35 million in cash as of the end of the third quarter, funds to fuel studies of vidofludimus calcium beyond the Phase III ENSURE studies in RMS continue to be a bottleneck for the company, though the company has cited an additional tranched $130 million in potential capital to fund company operations. Nonetheless, we view a potential partnership with Immunic for development of vidofludimus calcium in additional indications beyond RMS as worthwhile, and expect positive data from the Phase III ENSURE studies by year-end 2026, which evaluate vidofludimus calcium against placebo, not teriflunomide, to be a major catalyst for shares and reiterate our Outperform rating.
H.C. Wainwright
$10→$8
Buy
1303.51%
Upside
Reiterated
11/14/25
Roth MKM
$3
Buy
426.32%
Upside
Reiterated
11/14/25
Ladenburg Thalmann & Co.
$3
Buy
426.32%
Upside
Initiated
10/16/25
Chardan Capital
$3
Buy
426.32%
Upside
Initiated
09/29/25
B. Riley Securities
$5
Buy
777.19%
Upside
Reiterated
07/01/25
Brookline Capital Markets
$19→$22
Buy
3759.65%
Upside
Reiterated
04/30/25
Piper Sandler
$28
Buy
4812.28%
Upside
Reiterated
03/20/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
Buy
―
Reiterated
12/15/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Immunic (NASDAQ: IMUX)We continue to view vidofludimus calcium as a potent next-generation DHODH inhibitor and additional Nurr1 activation may provide additionalneuroprotection over teriflunomide without the need for liver monitoring. However, with $35 million in cash as of the end of the third quarter, funds to fuel studies of vidofludimus calcium beyond the Phase III ENSURE studies in RMS continue to be a bottleneck for the company, though the company has cited an additional tranched $130 million in potential capital to fund company operations. Nonetheless, we view a potential partnership with Immunic for development of vidofludimus calcium in additional indications beyond RMS as worthwhile, and expect positive data from the Phase III ENSURE studies by year-end 2026, which evaluate vidofludimus calcium against placebo, not teriflunomide, to be a major catalyst for shares and reiterate our Outperform rating.
H.C. Wainwright
$10→$8
Buy
1303.51%
Upside
Reiterated
11/14/25
Roth MKM
$3
Buy
426.32%
Upside
Reiterated
11/14/25
Ladenburg Thalmann & Co.
$3
Buy
426.32%
Upside
Initiated
10/16/25
Chardan Capital
$3
Buy
426.32%
Upside
Initiated
09/29/25
B. Riley Securities
$5
Buy
777.19%
Upside
Reiterated
07/01/25
Brookline Capital Markets
$19→$22
Buy
3759.65%
Upside
Reiterated
04/30/25
Piper Sandler
$28
Buy
4812.28%
Upside
Reiterated
03/20/25
Best Analysts Covering Immunic
1 Month
xxx
Success Rate
4/9 ratings generated profit
Average Return
+4.71%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 44.44% of your transactions generating a profit, with an average return of +4.71% per trade.
3 Months
xxx
Success Rate
4/9 ratings generated profit
Average Return
-2.23%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -2.23% per trade.
1 Year
Success Rate
1/9 ratings generated profit
Average Return
-31.21%
reiterated a buy rating 9 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -31.21% per trade.
2 Years
xxx
Success Rate
0/6 ratings generated profit
Average Return
-31.80%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -31.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IMUX Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
4
6
7
8
5
Buy
1
2
2
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
8
9
10
7
Each month's total comprises the sum of three months' worth of ratings.
IMUX Financial Forecast
IMUX Stock Forecast FAQ
What is IMUX’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunic’s 12-month average price target is 4.25.
What is IMUX’s upside potential, based on the analysts’ average price target?
Immunic has 645.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IMUX a Buy, Sell or Hold?
Immunic has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Immunic’s price target?
The average price target for Immunic is 4.25. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $3.00. The average price target represents 645.61% Increase from the current price of $0.57.
The highest analyst price target is $8.00 ,the lowest forecast is $3.00. The average price target represents 645.61% Increase from the current price of $0.57.
What do analysts say about Immunic?
Immunic’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of IMUX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.